<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21113">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02832037</url>
  </required_header>
  <id_info>
    <org_study_id>1346.9</org_study_id>
    <secondary_id>2016-000285-28</secondary_id>
    <nct_id>NCT02832037</nct_id>
  </id_info>
  <brief_title>Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia</brief_title>
  <official_title>A Phase II Randomised, Double-blinded, Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of 4 Oral Doses of BI 425809 Once Daily Over 12 Week Treatment Period in Patients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of the study is to investigate the efficacy, safety and pharmacokinetics of
      four different doses of BI 425809 once daily compared to placebo given for 12 weeks in
      patients with schizophrenia on stable antipsychotic treatment.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (masked roles unspecified)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in cognitive function as measured by the total score of the composite Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) score after 12 weeks of treatment</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in everyday functional capacity as measured by Schizophrenia Cognition Rating Scale (SCoRS) total score after 12 weeks of treatment</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with (Serious) Adverse Events (including clinically relevant abnormalities of physical examination, vital signs, Electrocardiogram (ECG) test and laboratory tests)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">504</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>BI 425809 dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 425809 dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 425809 dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 425809 dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 425809 dose 1</intervention_name>
    <arm_group_label>BI 425809 dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 425809 dose 2</intervention_name>
    <arm_group_label>BI 425809 dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 425809 dose 3</intervention_name>
    <arm_group_label>BI 425809 dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 425809 dose 4</intervention_name>
    <arm_group_label>BI 425809 dose 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>BI 425809 dose 1</arm_group_label>
    <arm_group_label>BI 425809 dose 2</arm_group_label>
    <arm_group_label>BI 425809 dose 3</arm_group_label>
    <arm_group_label>BI 425809 dose 4</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Men or women who are 18-50 years (inclusive) of age at time of consent

          -  Established schizophrenia with the following clinical features:

               -  Outpatient, with no hospitalization for worsening of schizophrenia within 3
                  months prior to randomisation

               -  Medically stable over the prior 4 weeks and psychiatrically stable without
                  symptom exacerbation within 3 months prior to randomisation

               -  patients who have no more than a moderate severe rating on the Positive and
                  Negative Symptom Scale (PANSS) positive items P1, P3-P7 and no more than a
                  moderate rating on the PANSS positive item P2

          -  Current antipsychotic and concomitant psychotropic medications as assessed at Visit 1
             must meet the criteria below:

               -  patients may have up to 2 antipsychotics (typical and/or atypical)

               -  patients must be maintained on current typical and/or atypical antipsychotics
                  other than Clozapine and on current dose for at least 4 weeks prior to
                  randomisation and/or maintained on current long acting injectable antipsychotics
                  and current dose for at least 3 months prior to randomization

               -  patients must be maintained on current concomitant psychotropic medications,
                  anticholinergics, antiepilectics and/or lithium for at least 3 months prior to
                  randomisation and on current dose for at least 4 weeks prior to randomisation

          -  Women of child-bearing potential must be ready and able to use highly effective
             methods of birth control that result in a low failure rate of less than 1% per year
             when used consistently and correctly.

          -  Patients must exhibit reliability, physiologic capability, and an educational level
             sufficient to comply with all protocol procedures, in the investigatorÂ´s opinion

          -  Patients must have an identified informant who will be consistent throughout the
             study.

          -  Further inclusion criteria apply

        Exclusion criteria:

          -  Patients who have a categorical diagnosis of another current major psychiatric
             disorder

          -  Diseases of the central nervous system that may impact cognitive test performance

          -  Movement disorder not currently controlled

          -  Patients receiving another investigational drug or procedure within 30 days or 6
             half-lives (whichever is longer) or recent participation in another trial with any
             cognitive enhancing therapy

          -  Recent participation in formal cognitive remediation program

          -  Recent electroconvulsive therapy

          -  Patients who have been on BI 409306, encenicline or other investigational drug
             testing effects on cognition in schizophrenia within the last 6 months prior to
             randomisation or who have previously been on bitopertin

          -  Participation in a clinical trial with repeated Measurement and Treatment Research to
             Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB)
             assessments within the last 6 months

          -  Patients who required change in benzodiazepine or sleep medication regimen within the
             last 4 weeks prior to randomisation

          -  Treatment with Clozapine within 6 months prior to randomisation

          -  Treatment with medical devices (e.g. Transcranial Magnetic Stimulation (TMS),
             neurofeedback) for any psychiatric condition within the last 3 months prior to
             randomisation

          -  Patients taking strong or moderate Cytochrome P450 (CYPA4) inhibitors or inducers
             within the last 30 days prior to randomization

          -  Any suicidal behavior in the past 2 years (i.e. actual attempt, interrupted attempt,
             aborted attempt, or preparatory acts or behavior) prior to randomisation

          -  Any suicidal ideation of type 4 or 5 in the Columbia Suicidal Severity Rating Scale
             (C-SSRS) in the past 3 months (i.e. active suicidal thought with intent but without
             specific plan, or active suicidal thought with plan and intent) prior to
             randomisation

          -  Known history of Human Immunodeficiency Virus (HIV) infection, Hepatitis B or C
             infection

          -  Hemoglobin less than 130 g/L (13g/dL) in men or 120g/L (12g/dL) in women

          -  History of hemoglobinopathy such as thalassemia major or sickle-cell anemia

          -  Women who are pregnant, nursing, or who plan to become pregnant while in the trial or
             men who are able to father a child, unwilling to be abstinent or use adequate
             contraception for the duration of the study participation and for at least 28 days
             after treatment has ended

          -  Significant history of drug abuse disorder (including alcohol) within the last 6
             months prior to informed consent or a positive urine drug screen at screening

          -  Further exclusion criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Westerstede</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 22, 2017</lastchanged_date>
  <firstreceived_date>July 7, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
